Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Solicitation from Department of Defense.
Data as of Nov 16, 2026 · Sources: SAM.gov and Grants.gov · About this data
Notice details
- Agency
- Department of Defense
- Sub-tier agency
- DEFENSE HEALTH AGENCY (DHA)
- Notice type
- Solicitation
- Solicitation number
- HT9402-27-Q-9102
- Product/service code
- 6505
- Place of performance
- San Antonio, Texas
- Posted
- Nov 13, 2026
- Response deadline
- Nov 30, 2026
- Source
- SAM.gov
Description
The Department of War (DoW) is required by law (10 U.S.C. � 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 newly approved drugs will be reviewed: Atebrioz � Skeletal Muscle Relaxants and Combinations � Subclass: NA Emcitate � Thyroid and Antithyroid Agents � Subclass: NA Hibsago � Hepatitis B Agents � Subclass: NA Juvmo � Parkinsons Agents � Subclass
Summarized from the official notice. The description is shortened; read the full text on the official notice.
Official notice
Requirements and amendments are controlled by the official notice.
DSE verdict
The DSE fit verdict for this notice is available to DSE GovCon subscribers. It is not published on this page.
See DSE GovCon plans →Similar open notices
- Epinephrine InjectorClosing in 14 daysPosted Nov 5, 2026 · Due Nov 30, 2026
- Atropine Auto-InjectorClosing in 15 daysPosted Oct 30, 2026 · Due Dec 1, 2026
- Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount ProgramClosing in 21 daysPosted Nov 13, 2026 · Due Dec 7, 2026
- FentanylOpen, no deadline statedPosted Nov 5, 2026 · Due Not stated
- Morphine Sulfate SolutionOpen, no deadline statedPosted Sep 22, 2026 · Due Not stated
Get free alerts
Email alerts for notices like this one are free on DSE GovCon Intelligence.
Set up free alerts →Frequently asked questions
When is the response deadline?
The published deadline is Nov 30, 2026. That is 14 days after the data date.
What NAICS code applies?
NAICS 325412, Pharmaceutical Preparation Manufacturing.
Which agency issued this notice?
Department of Defense.
Where is the official notice?
The link under Official notice opens the source listing.